Overcoming Clinical Challenges in BRIC Markets - Brazil
Thomson Reuters Cortellis Competitive Intelligence
Figure 1A: While many still tout the benefits for conducting clinical trials in emerging markets, data from Cortellis finds that drug development in most of the BRIC (Brazil, Russia, India and China) countries is on the decline. Sponsors are largely pulling back or out completely due to increasingly complex regulatory guidelines, corruption, patent challenges, losses to generics, and import/export delays.
Figure 1C: For clinical trials reported in the BRIC countries by phase, Russia and China feature the highest number of unreported phases. Russia edges out the remaining countries on Phase III trials.
Figure 2A: Although improving, Brazil’s regulatory approval process for clinical trials still remains the lengthiest in Latin America and can take anywhere from five to 12 months. ANVISA, the national health surveillance agency for Brazil, operates much like the FDA. The country’s compassionate use program, approved in August 2013, guarantees free orphan drug supply to those who have participated in a Phase III trial and benefitted from the drug. Because the patient population for a rare disease is limited by nature, the sponsor’s Brazilian market for the respective orphan drug may be entirely comprised of its successful Phase III trial patients, negating any profit they may make in the country.
Figure 2B: Overall, trials have declined in Brazil since 2011, however, local companies are filling the gaps, as well as university and government trials. Novartis remains a key player in the country, along with Roche and AstraZeneca. Pfizer, Sanofi, and GSK have decreased their presence.
SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here: http://interest.science.thomsonreuters.com/forms/Verify?doc=http://images.info.science.thomsonreuters.biz/Web/ThomsonReutersScience/{569dbe1e-07d1-49ff-9bbe-d9c515a8a526}_BRIC_nations_white_paper_final__201404.pdf&rt=Marketing&sbu=Life%20Sciences&cid=70170000000Ue0T&cn=LS%20-%20201307%20Life%20Sciences%20Connect%20Blog%20Gated%20Forms
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
